ulipristal acetate and Uterine Neoplasms
ulipristal acetate has been researched along with Uterine Neoplasms in 146 studies
Research
Studies (146)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 108 (73.97) | 24.3611 |
2020's | 38 (26.03) | 2.80 |
Authors
Authors | Studies |
---|---|
Bet, PM; Clark, TJ; de Lange, ME; Hehenkamp, WJK; Huirne, JAF; Middelkoop, MA; Mol, BWJ | 1 |
Aaltonen, LA; Bützow, R; Heikinheimo, O; Ilves, ST; Kaasinen, E; Karhu, A; Kaukomaa, J; Kolterud, Å; Kopp Kallner, H; Kuisma, H; Mäkinen, N; Palin, K; Pasanen, A; Patomo, J; Välimäki, N | 1 |
Arzoo, S; Ferdous, NE; Khatun, R; Mahmood, S; Rahman, R; Tanzin, F; Yousuf, S | 1 |
Choi, J; Kim, HG; Kyeong, HK; Na, YJ | 1 |
Cho, YJ; Choi, JJ; Choi, JY; Hwang, JR; Kim, HS; Lee, JW; Ryu, JY; Sa, JK | 1 |
Angioni, S; Castellacci, E; Di Spiezio Sardo, A; Franchini, M; Giarrè, G; Malune, ME; Saccone, G | 1 |
Bongers, MY; de Milliano, I; Hehenkamp, WJK; Huirne, JAF; Radder, C; Thurkow, AL; van de Lande, J; van de Ven, PM; van Vliet, H | 1 |
Cosyns, S; De Vree, B; Donnez, O; Godin, PA; Luyckx, M; Nisolle, M; Verguts, J | 1 |
Allaire, C; Laberge, PY; Leyland, N; Murji, A; Singh, SS; Vilos, GA | 1 |
Andrasova, M; Boudova, B; Dundr, P; Kuzel, D; Lisa, Z; Mara, M | 1 |
Arena, A; Degli Esposti, E; Del Forno, S; Iodice, R; Leonardi, D; Paradisi, R; Raimondo, D; Salucci, P; Seracchioli, R | 1 |
Al-Hendy, A; Anam, A; Burman, A; Flannery, C; Kisanga, EP; Millard, CEF; Small, B; Whirledge, S | 1 |
De Milliano, I; Frijlingh, M; Hehenkamp, WJK; Huirne, JAF | 1 |
Acosta, K; Binkley, P; Dileep, KV; Nair, HB; Nickisch, K; Santhamma, B; Schenken, R; Zhang, KYJ | 1 |
Ciarmela, P; Del Bello, B; Luisi, S; Maellaro, E; Marcolongo, P; Petraglia, F; Sorbi, F | 1 |
Benedetti Panici, P; Del Negro, V; Di Donato, V; Fischetti, M; Fracassi, A; Muzii, L; Palaia, I; Schiavi, M | 1 |
Barra, F; Cianci, A; Ferrero, S; Paudice, M; Scala, C; Vellone, VG; Vitale, SG | 1 |
Capmas, P; Fernandez, H; Laberge, P; Pourcelot, AG | 1 |
Kosmas, IP; Malvasi, A; Mynbaev, OA; Sparic, R; Tinelli, A; Vergara, D | 1 |
Barra, F; Caruso, S; Cianci, A; Ciebiera, M; Ferrero, S; Marín-Buck, A; Török, P; Vilos, GA; Vitagliano, A; Vitale, SG | 1 |
Centini, G; De Leo, V; Morgante, G; Orvieto, R; Troìa, L | 1 |
Bosmans, JE; De Milliano, I; Geomini, PMAJ; Hehenkamp, WJK; Huirne, JAF; Kwee, J; Middelkoop, MA; Schoot, BC; Van Baal, M | 1 |
Avigan, MI; Brinker, A; Dimick-Santos, L; Jones, SC; Kang, S | 1 |
Bucella, D; Fastrez, M; Revercez, P; Rozenberg, S; Vandromme, J | 1 |
Dolmans, MM; Donnez, J | 2 |
De Ponti, F; Gatti, M; Poluzzi, E; Raschi, E | 1 |
Ambrosio, D; Calagna, G; Cianci, A; Colacurci, N; Cucinella, G; De Franciscis, P; Labriola, D; Riemma, G; Schiattarella, A; Vitale, SG | 1 |
Ashkenas, J; Janiszewski, P; Kives, S; Leyland, N; Strand, T; Thiel, J | 1 |
Aloisio, M; Arrigoni, G; Athanasakis, E; Biffi, S; De Spelorzi, YCC; Di Lorenzo, G; Franchin, C; Gaita, B; Licastro, D; Monasta, L; Ricci, G; Romano, F; Scrimin, F; Stabile, G; Ura, B | 1 |
Ekanem, E; Talaulikar, V | 1 |
Bet, PM; Drenth, JPH; Hehenkamp, WJK; Huirne, JAF; Middelkoop, MA | 1 |
Yoon, EL; Yuk, JS | 1 |
Nakano, Y; Osuga, Y; Takanashi, M; Yamauchi, Y | 1 |
D'Oria, O; Gustapane, S; Licchelli, M; Panese, G; Tinelli, A | 1 |
Chodankar, RR; Critchley, HOD; Murray, A; Nicol, M; Whitaker, LHR; Williams, ARW | 1 |
Dinis-Oliveira, RJ | 1 |
Bernal, L; Carmona, F; Carrion, A; Castelo-Branco, C; Feixas, G; Gracia, M; Martínez-Zamora, MÁ; Nicolás, I; Quintas, L; Rius, M | 1 |
Barnott, E; Black, L; Gould, A; Jack, A; Kastora, SL; Kounidas, G; Morgan, D; Poobalan, A; Robinson-Burke, T; Urquhart, G | 1 |
Avilés Dorlhiac, R; Navarro Plazaola, N; Vega Chacana, M | 1 |
Murakawa, H; Nakano, Y; Osuga, Y; Yamauchi, Y | 1 |
Capmas, P; Fernandez, H; Pourcelot, AG | 1 |
Chow, TL; Murji, A; Sobel, ML; Whitaker, L | 1 |
Gilles, C; Manigart, Y; Pazzaglia, E; Praet, J; Rozenberg, S; Vandromme, J | 1 |
Borja De Mozota, D; Kadhel, P; Smail, M | 1 |
Agostini, A; Brun, JL; Darai, E; Descamps, P; Fernandez, H; Koskas, M; Lopès, P | 1 |
Chill, HH; Reuveni Salzman, A; Safrai, M; Shushan, A | 1 |
Águas, F; Faustino, F; Martinho, M; Reis, J | 1 |
Fernandez, H; Jourdain, O; Lafuma, A; Lehmann, M; Trancart, M; Villefranque, V | 1 |
Bergeron, C; Chamorro-Santos, C; Crespo-Lora, V; Cruz-Viruel, N; Nogales, FF | 1 |
Britten, J; Catherino, WH; Cox, J; Lewis, T; Malik, M | 1 |
Biglia, N; D'alonzo, M; Garbagnati, M; Menato, G; Modaffari, P; Pecchio, S | 1 |
Mallick, R; Odejinmi, F; Oliver, R | 1 |
Barreira, M; Courtoy, GE; Dolmans, MM; Donnez, J; Luyckx, M; Marbaix, E | 1 |
Barra, F; Ferrero, S; Vellone, VG | 1 |
Belland, L; Leyland, N; Murji, A; Singh, SS; von Riedemann, S | 1 |
Brun, JL; Froeliger, A; Monseau-Thiburce, AC; Rajaonarison, J; Randriamboavonjy, R; Vogler, A | 1 |
Dutta, D; Powell, M | 1 |
Bouchard, P; Chabbert-Buffet, N; Daraï, E; Kolanska, K | 1 |
Badiani, B; Chiumente, M; Messori, A | 1 |
Courtoy, GE; de Codt, M; Dolmans, MM; Donnez, J; Henriet, P; Luyckx, M; Marbaix, E | 1 |
Al-Hendy, A; Blakesley, RE; Catherino, W; Chan, A; Segars, JH; Simon, JA; Sniukiene, V | 1 |
Arriagada, P; Dolmans, MM; Donnez, J; Donnez, O | 2 |
Ciebiera, M; Jakiel, G; Nowicka, G; Słabuszewska-Jóźwiak, A; Wrzosek, M; Włodarczyk, M | 1 |
Irani, S; Pounds, R; Pradhan, P; Woodhead, N | 1 |
Bae, HS; Jung, YW; Kim, MK; Kim, ML; Seong, SJ; Shim, SS; Yun, BS | 1 |
Courtoy, GE; Dolmans, MM; Donnez, J; Donnez, O | 2 |
Ajossa, S; Corda, V; Giancane, E; Mais, V; Marotto, MF; Melis, GB; Neri, M; Paoletti, AM; Pilloni, M; Piras, B; Saba, A | 1 |
Ambroise, J; Arriagada, P; Courtoy, GE; Dolmans, MM; Donnez, J; Luyckx, M; Marbaix, E | 1 |
Biscette, SM; Ito, T; Jan, AG; Kim, JHJ; Mattingly, PJ | 1 |
Angelico, G; Arciuolo, D; Fanfani, F; Inzani, F; Romualdi, D; Santoro, A; Scambia, G; Zannoni, GF | 1 |
De Gasperis-Brigante, C; Kives, S; Murji, A; Singh, SS; Vilos, G | 1 |
Armstrong, CR; Baig, KM; Brennan, JT; Britten, J; Chang, S; Driggers, PH; Jorge, S; Malik, M; Ng, SSM; Segars, JH; Su, SC | 1 |
Fernandez, H | 1 |
Chan, A; Gee, P; Gillard, P; Harrington, A; Kimble, T; Kroll, R; Liu, JH; Lukes, A; Mallick, M; Shulman, LP; Sniukiene, V; Soper, D | 1 |
Camilli, S; Conway, F; Exacoustos, C; Martire, FG; Morosetti, G; Piccione, E; Sorrenti, G; Zupi, E | 1 |
Arriagada, P; Donnez, J; Larrey, D; Marciniak, M | 1 |
Carmona, F; Gracia, M; Martínez-Zamora, MÁ; Nonell, R; Quintas, L; Rius, M; Ros, C | 1 |
De Wilde, RL; Ebert, AD; Rabe, T; Roemer, T; Saenger, N; Tinneberg, HR; Wallwiener, M | 1 |
Barra, F; Ferrero, S; Scala, C; Vellone, VG | 1 |
Britten, JL; Catherino, WH; Lewis, TD; Malik, M | 1 |
Courtoy, GE; Dolmans, MM; Donnez, J | 1 |
Ciebiera, M; Jakiel, G; Męczekalski, B; Łukaszuk, K | 1 |
Han, SJ; Hong, YH; Jee, BC; Kim, SK; Lee, D | 1 |
Chang, MC; Latta, E | 1 |
Ajossa, S; Cappai, R; Coghe, F; Corda, V; Giancane, E; Mais, V; Marotto, MF; Melis, GB; Neri, M; Orani, MP; Paoletti, AM; Pilloni, M; Piras, B; Ronchi, A; Saba, A; Vallerino, V; Zedda, P | 1 |
Conzadori, S; Greco, P; Indraccolo, U | 1 |
Britten, J; Catherino, WH; Cox, J; Lewis, TD; Malik, M; Parikh, T | 1 |
Aractingi, S; Bendifallah, S; Bergeron, C; Canlorbe, G; Capmas, P; Chabbert-Buffet, N; Daraï, E; Kolanska, K; Koskas, M; Mekinian, A; Varinot, J | 1 |
Collinet, P; Cosson, M; Giraudet, G; Pécout, M; Rubod, C | 1 |
Ghonim, M; Magdy, R; Nabhan, A; Sabbour, M | 1 |
Barra, V; Bellone, E; Biscione, A; Luisi, S; Severi, FM | 1 |
Kotarski, J; Szamatowicz, M | 1 |
Brazert, M; Korman, MP; Pawelczyk, LA | 1 |
Fuster, S; Higueras, G; Monleón Sancho, J; Morcillo, I; Romaguera, E; Romero, A | 1 |
Barlow, DH; Bestel, E; Fauser, BC; Lumsden, MA; Terrill, P | 1 |
Ágh, T; Józwiak-Hagymásy, J; Kaló, Z; Kovács, G; László, Á; Merész, G; Nagy, B; Timár, G; Vámossy, I; Vokó, Z | 1 |
Barlow, DH; Bestel, E; Bouchard, P; Donnez, J; Donnez, O; Fauser, BC; Loumaye, E; Nouri, K; Osterloh, I; Palacios, S; Tomaszewski, J; Vázquez, F | 1 |
Bastianelli, C; Benagiano, G; Brosens, I; Farris, M | 1 |
Closon, F; Firquet, A; Nisolle, M; Pintiaux, A; Top, M | 1 |
Critchley, HO; Whitaker, LH; Williams, AR | 1 |
Gadomska, H; Grzechocinska, B; Wielgos, M; Zygula, A | 1 |
Carrarelli, P; Castellucci, M; Ciarmela, P; Islam, MS; Janjusevic, M; Petraglia, F; Tosti, C; Zupi, E | 1 |
Dolmans, MM; Donnez, J; Donnez, O | 2 |
Gotteland, JP; Pohl, O; Zobrist, RH | 1 |
Dolmans, MM; Donnez, J; Jadoul, P; Luyckx, M; Squifflet, JL; Votino, R | 1 |
Belland, L; Singh, SS | 1 |
Pérez-López, FR | 1 |
Manyonda, I; Talaulikar, VS | 1 |
Arhendt, HJ; Barlow, DH; Bestel, E; Bouchard, P; Donnez, J; Donnez, O; Dumitrascu, MC; Fauser, BC; Fernandez, H; Hudecek, R; Kasilovskiene, Z; Loumaye, E; Matule, D; Osterloh, I; Terrill, P; Zatik, J | 1 |
Galliano, D | 1 |
Bizzarri, N; Candiani, M; Ferrero, S; Leone Roberti Maggiore, U; Scala, C; Tafi, E; Venturini, PL | 1 |
Courtoy, GE; Dolmans, MM; Donnez, J; Marbaix, E | 1 |
Cha, DH; Kim, JY; Kim, ML; Park, JE; Seong, SJ; Shim, JY; Yun, BS | 1 |
Bulun, SE; Moravek, MB | 1 |
Bizzarri, N; Ferrero, S; Ghirardi, V; Remorgida, V; Venturini, PL | 1 |
Sanders, B | 1 |
Ahrendt, HJ; Barlow, DH; Bestel, E; Bouchard, P; Donnez, J; Donnez, O; Dumitrascu, MC; Fauser, BC; Fernandez, H; Hudecek, R; Kasilovskiene, Z; Loumaye, E; Matule, D; Zatik, J | 1 |
Boutas, I; Kalampokas, E; Kalampokas, T; Kamath, M | 1 |
Koskas, M; Luton, D; Puchar, A | 1 |
Abraham, T; Arian, SE; Bartels, CB; Cayton, KC; Chuong, FS; Holthouser, K; Segars, JH | 1 |
Centini, G; Kashani, BN; Morelli, SS; Petraglia, F; Weiss, G | 1 |
Murad, K | 1 |
Arendas, K; Leyland, NA | 1 |
Engl, B; Graziano, A; Lo Monte, G; Marci, R; Piva, I | 1 |
Maratea, D | 1 |
Dubuisson, J; Marci, R; Petignat, P; Willame, A | 1 |
Póka, R; Török, P | 1 |
Biterna Tejeiro, A; Fernández de Castillo Torras, L; Pla Farnós, MJ; Ponce Sebastià, J | 1 |
Chow, T; Crosier, R; Murji, A; Shirreff, L; Ye, XY | 1 |
Istre, O | 1 |
Alessandri, F; Ferrero, S; Leone Roberti Maggiore, U; Vellone, VG; Venturini, PL | 1 |
Pazzaglia, E; Praet, J; Rozenberg, S; Vandromme, J | 1 |
Arriagada, P; Costa, AP; Fernandez, H; Powell, M; Schmidt, T; Thaler, C | 1 |
Bateman, J; Bougie, O; Islam, S; Singh, S | 1 |
Brodowska, A; Marciniak, A; Nawrocka-Rutkowska, J; Starczewski, A; Szydłowska, I; Wiśniewska, B | 1 |
Bouchard, P | 1 |
Bestel, E; Bouchard, P; Donnez, J; Ivanova, T; Jilla, MP; Loumaye, E; Mara, M; Osterloh, I; Puscasiu, L; Tatarchuk, TF; Terrill, P; Ugocsai, G; Zakharenko, NF | 1 |
Baró, F; Bestel, E; Bouchard, P; Donnez, J; Lemieszczuk, B; Loumaye, E; Nouri, K; Osterloh, I; Selvaggi, L; Sodowski, K; Terrill, P; Tomaszewski, J; Vázquez, F | 1 |
Stewart, EA | 1 |
Croxtall, JD | 1 |
Angiolucci, M; Guerriero, S; Lello, S; Maricosu, G; Marotto, MF; Melis, GB; Orru', MM; Paoletti, AM; Pilloni, M; Piras, B | 1 |
Manyonda, IT; Talaulikar, VS | 1 |
Reviews
52 review(s) available for ulipristal acetate and Uterine Neoplasms
Article | Year |
---|---|
Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids.
Topics: Europe; Female; Humans; Leiomyoma; Norpregnadienes; Uterine Neoplasms | 2022 |
The Biological Impact of Ulipristal Acetate on Cellular Networks Regulating Uterine Leiomyoma Growth.
Topics: Adult; Female; Humans; In Vitro Techniques; Leiomyoma; Norpregnadienes; Signal Transduction; Uterine Neoplasms | 2020 |
Ulipristal Acetate Before Hysteroscopic Myomectomy: A Systematic Review.
Topics: Female; Humans; Hysteroscopy; Leiomyoma; Norpregnadienes; Preoperative Care; Receptors, Progesterone; Treatment Outcome; Uterine Myomectomy; Uterine Neoplasms | 2020 |
Hormone therapy for intramural myoma-related infertility from ulipristal acetate to GnRH antagonist: a review.
Topics: Female; Hormone Antagonists; Humans; Infertility, Female; Leiomyoma; Norpregnadienes; Uterine Neoplasms | 2020 |
Medical Therapy for Fibroids: What Next for Ulipristal Acetate?
Topics: Female; Humans; Leiomyoma; Menorrhagia; Norpregnadienes; Uterine Neoplasms | 2021 |
Risk-efficacy balance of ulipristal acetate compared to surgical alternatives.
Topics: Female; Humans; Leiomyoma; Norpregnadienes; Prospective Studies; Quality of Life; Uterine Neoplasms | 2021 |
Efficacy of ulipristal acetate in women with fibroid induced menorrhagia: A systematic review and meta-analysis.
Topics: Adult; Contraceptive Agents; Female; Humans; Leiomyoma; Menorrhagia; Norpregnadienes; Uterine Neoplasms | 2021 |
Effects of ulipristal acetate in patients with symptomatic uterine fibroids.
Topics: Female; Humans; Leiomyoma; Norpregnadienes; Quality of Life; Systematic Reviews as Topic; Treatment Outcome; Uterine Neoplasms | 2021 |
Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?
Topics: Contraceptive Agents, Female; Female; Fertility; Humans; Leiomyoma; Menorrhagia; Norpregnadienes; Preoperative Care; Receptors, Progesterone; Uterine Neoplasms | 2017 |
Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Topics: Amenorrhea; Antineoplastic Agents, Hormonal; Estrenes; Female; Humans; Leiomyoma; Leuprolide; Menstruation; Mifepristone; Norpregnadienes; Oximes; Pelvic Pain; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone; Uterine Neoplasms | 2017 |
The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology.
Topics: Contraception, Postcoital; Contraceptive Agents, Female; Contraceptives, Postcoital; Female; Humans; Leiomyoma; Norpregnadienes; Receptors, Progesterone; Uterine Neoplasms | 2017 |
Update on medical treatment of uterine fibroids.
Topics: Adult; Contraceptive Agents, Female; Female; Humans; Leiomyoma; Norpregnadienes; Quality of Life; Uterine Neoplasms | 2017 |
Unexpected uterine leiomyosarcoma in a woman with multiple myomas treated with ulipristal acetate: case report and literature review.
Topics: Female; Humans; Leiomyomatosis; Leiomyosarcoma; Middle Aged; Norpregnadienes; Uterine Neoplasms | 2018 |
Is ulipristal acetate the new drug of choice for the medical management of uterine fibroids? Res ipsa loquitur?
Topics: Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Leiomyoma; Norpregnadienes; Severity of Illness Index; Uterine Neoplasms; Women's Health | 2017 |
Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
Topics: Administration, Oral; Animals; Biological Availability; Female; Humans; Leiomyoma; Norpregnadienes; Receptors, Progesterone; Time Factors; Uterine Neoplasms | 2018 |
The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
Topics: Contraceptive Agents, Female; Disease Management; Estrenes; Female; Forecasting; Humans; Leiomyoma; Mifepristone; Norpregnadienes; Oximes; Population Growth; Receptors, Progesterone; Steroids; Uterine Neoplasms | 2018 |
Esmya
Topics: Adult; Clinical Trials, Phase III as Topic; Contraceptive Agents, Female; Female; Humans; Leiomyoma; Menorrhagia; Norpregnadienes; Uterine Hemorrhage; Uterine Neoplasms | 2016 |
Selective progesterone receptor modulators: current applications and perspectives.
Topics: Abortion, Induced; Endometriosis; Female; Humans; Leiomyoma; Mifepristone; Norpregnadienes; Pregnancy; Progesterone; Receptors, Progesterone; Uterine Hemorrhage; Uterine Neoplasms | 2018 |
Emerging treatment options for uterine fibroids.
Topics: Drug Design; Female; Fertility Preservation; Humans; Leiomyoma; Norpregnadienes; Receptors, Progesterone; Uterine Neoplasms | 2018 |
Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review.
Topics: Female; Humans; Leiomyoma; Menorrhagia; Norpregnadienes; Quality of Life; Treatment Outcome; Uterine Neoplasms | 2018 |
Vilaprisan for treating uterine fibroids.
Topics: Animals; Female; Humans; Leiomyoma; Norpregnadienes; Receptors, Progesterone; Steroids; Time Factors; Uterine Hemorrhage; Uterine Neoplasms | 2018 |
Alternatives to excisional therapy: a clinical review of our current options to conservatively manage symptomatic leiomyomas.
Topics: Antifibrinolytic Agents; Aromatase Inhibitors; Female; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Magnetic Resonance Imaging, Interventional; Norpregnadienes; Radiofrequency Ablation; Receptors, Progesterone; Tranexamic Acid; Ultrasonic Therapy; Uterine Artery Embolization; Uterine Neoplasms | 2018 |
Pregnancy Outcomes Following Ulipristal Acetate for Uterine Fibroids: A Systematic Review.
Topics: Canada; Female; Humans; Leiomyoma; Norpregnadienes; Pregnancy; Pregnancy Outcome; Uterine Neoplasms | 2018 |
Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program.
Topics: Chemical and Drug Induced Liver Injury; Contraceptive Agents, Female; Female; Humans; Leiomyoma; Liver Function Tests; Norpregnadienes; Uterine Neoplasms | 2018 |
Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.
Topics: Female; Humans; Leiomyoma; Norpregnadienes; Practice Patterns, Physicians'; Receptors, Progesterone; Uterine Neoplasms | 2018 |
Ulipristal Acetate before Hysteroscopic and Laparoscopic Surgery for Uterine Myomas: Help or Hindrance?
Topics: Adult; Endometrium; Female; Humans; Hysteroscopy; Laparoscopy; Leiomyoma; Middle Aged; Norpregnadienes; Preoperative Period; Prospective Studies; Retrospective Studies; Treatment Outcome; Uterine Myomectomy; Uterine Neoplasms | 2019 |
Fibroid management in premenopausal women.
Topics: Chemical and Drug Induced Liver Injury; Female; Humans; Hysterectomy; Leiomyoma; Norpregnadienes; Premenopause; Preoperative Care; Progesterone; Randomized Controlled Trials as Topic; Risk Factors; Uterine Neoplasms | 2019 |
A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids.
Topics: Adult; Amenorrhea; Female; Humans; Leiomyoma; Menorrhagia; Norpregnadienes; Quality of Life; Randomized Controlled Trials as Topic; Uterine Neoplasms | 2019 |
[Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hormone Antagonists; Humans; Leiomyoma; Norpregnadienes; Progesterone; Randomized Controlled Trials as Topic; Receptors, Progesterone; Uterine Neoplasms | 2013 |
[Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hormone Antagonists; Humans; Leiomyoma; Norpregnadienes; Progesterone; Randomized Controlled Trials as Topic; Receptors, Progesterone; Uterine Neoplasms | 2013 |
[Ulipristal acetate, 5mg: a new alternative].
Topics: Antineoplastic Agents, Hormonal; Female; Humans; Leiomyoma; Norpregnadienes; Treatment Outcome; Uterine Neoplasms | 2013 |
Selective progesterone receptor modulators: an update.
Topics: Adenomyosis; Animals; Clinical Trials as Topic; Contraception, Postcoital; Contraceptive Agents, Female; Contraceptives, Postcoital; Endometriosis; Estrenes; Female; Hormone Antagonists; Humans; Leiomyoma; Levonorgestrel; Mifepristone; Norpregnadienes; Oximes; Receptors, Progesterone; Uterine Neoplasms | 2014 |
Selective progesterone receptor modulators.
Topics: Breast Neoplasms; Contraceptives, Postcoital; Endometriosis; Female; Hormone Antagonists; Humans; Leiomyoma; Menorrhagia; Norpregnadienes; Quality of Life; Receptors, Progesterone; Uterine Neoplasms | 2014 |
With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice?
Topics: Antineoplastic Agents, Hormonal; Female; Gonadotropin-Releasing Hormone; Humans; Hysterectomy; Laparoscopy; Leiomyoma; Norpregnadienes; Practice Guidelines as Topic; Progestins; Receptors, Progesterone; Uterine Neoplasms | 2014 |
The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Biological Availability; Biotransformation; Cytochrome P-450 CYP3A; Drug Administration Schedule; Drug Interactions; Female; Half-Life; Humans; Leiomyoma; Norpregnadienes; Risk Assessment; Uterine Neoplasms | 2015 |
Contemporary management of uterine fibroids: focus on emerging medical treatments.
Topics: Adult; Canada; Female; Gynecologic Surgical Procedures; Hormone Antagonists; Humans; Leiomyoma; Menorrhagia; Norpregnadienes; Uterine Neoplasms; Watchful Waiting | 2015 |
Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Topics: Female; Humans; Leiomyoma; Menorrhagia; Norpregnadienes; Quality of Life; Receptors, Progesterone; Uterine Hemorrhage; Uterine Neoplasms | 2015 |
Ulipristal acetate in uterine fibroids.
Topics: Female; Humans; Leiomyoma; Norpregnadienes; Quality of Life; Uterine Neoplasms | 2015 |
Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Topics: Animals; Apoptosis; Cell Proliferation; Female; Humans; Leiomyoma; Norpregnadienes; Quality of Life; Receptors, Progesterone; Time Factors; Uterine Neoplasms | 2015 |
Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution.
Topics: DNA Mutational Analysis; Estrogens; Exons; Female; Genetic Predisposition to Disease; Genotype; HMGA2 Protein; Hormones; Humans; Leiomyoma; Mediator Complex; Mutation; Norpregnadienes; Progesterone; Uterine Neoplasms | 2015 |
Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators.
Topics: Adult; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Female; Fertility Preservation; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Patient Selection; Receptors, Progesterone; Treatment Outcome; Uterine Neoplasms | 2015 |
Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis.
Topics: Female; Humans; Leiomyoma; Norpregnadienes; Receptors, Progesterone; Uterine Neoplasms | 2016 |
Ulipristal acetate for uterine fibroid-related symptoms.
Topics: Animals; Clinical Trials as Topic; Drug Interactions; Female; Humans; Leiomyoma; Norpregnadienes; Receptors, Progesterone; Uterine Neoplasms | 2015 |
An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review.
Topics: Androgens; Aromatase Inhibitors; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Curcumin; Delayed-Action Preparations; Drugs, Chinese Herbal; Estradiol; Estrenes; Estrogen Receptor Antagonists; Evidence-Based Medicine; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Medroxyprogesterone Acetate; Mifepristone; Neoadjuvant Therapy; Norpregnadienes; Oximes; Plant Extracts; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tea; Uterine Myomectomy; Uterine Neoplasms; Vitamin D; Vitamins | 2016 |
Role of Medical Management for Uterine Leiomyomas.
Topics: Antifibrinolytic Agents; Aromatase Inhibitors; Cabergoline; Cholecalciferol; Contraceptive Agents, Female; Contraceptives, Oral, Hormonal; Contraceptives, Oral, Synthetic; Danazol; Dopamine Agonists; Ergolines; Estrenes; Estrogen Antagonists; Female; Gestrinone; Gonadotropin-Releasing Hormone; Humans; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Mifepristone; Norpregnadienes; Oximes; Patient Care Planning; Selective Estrogen Receptor Modulators; Somatostatin; Tranexamic Acid; Uterine Neoplasms; Vitamins | 2016 |
The place of selective progesterone receptor modulators in myoma therapy.
Topics: Female; Humans; Leiomyoma; Norpregnadienes; Progesterone; Receptors, Progesterone; Uterine Hemorrhage; Uterine Neoplasms | 2016 |
Uterine fibroid management: from the present to the future.
Topics: Contraceptive Agents; Female; Humans; Hysterectomy; Leiomyoma; Magnetic Resonance Imaging; Norpregnadienes; Pelvic Pain; Progesterone; Randomized Controlled Trials as Topic; Risk Factors; Uterine Artery; Uterine Neoplasms | 2016 |
Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Topics: Female; Humans; Leiomyoma; Norpregnadienes; Randomized Controlled Trials as Topic; Receptors, Progesterone; Uterine Neoplasms | 2016 |
[New methods of uterine fibroids treatment].
Topics: Antineoplastic Agents; Female; High-Intensity Focused Ultrasound Ablation; Humans; Leiomyoma; Norpregnadienes; Uterine Neoplasms | 2016 |
Current and future medical treatments for menometrorrhagia during the premenopause.
Topics: Adolescent; Adult; Contraceptives, Oral; Endometrial Neoplasms; Female; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Levonorgestrel; Menorrhagia; Metrorrhagia; Mifepristone; Norpregnadienes; Polyps; Premenopause; Progestins; Randomized Controlled Trials as Topic; Receptors, Progesterone; Uterine Neoplasms | 2011 |
Ulipristal acetate: in uterine fibroids.
Topics: Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; Leiomyoma; Norpregnadienes; Randomized Controlled Trials as Topic; Uterine Hemorrhage; Uterine Neoplasms | 2012 |
Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids.
Topics: Adult; Age Factors; Cohort Studies; Contraceptive Agents; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hysterectomy; Leiomyoma; Middle Aged; Needs Assessment; Norpregnadienes; Quality of Life; Risk Assessment; Severity of Illness Index; Treatment Outcome; United Kingdom; Uterine Neoplasms | 2012 |
Trials
18 trial(s) available for ulipristal acetate and Uterine Neoplasms
Article | Year |
---|---|
Efficacy and Safety of Repeated Use of Ulipristal Acetate in Uterine Fibroids.
Topics: Bangladesh; Female; Humans; Leiomyoma; Quality of Life; Uterine Neoplasms | 2023 |
Ulipristal acetate vs gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): Short-term results of a double-blind randomized controlled trial.
Topics: Adult; Blood Loss, Surgical; Contraceptive Agents, Hormonal; Double-Blind Method; Female; Gonadotropin-Releasing Hormone; Humans; Laparoscopy; Leiomyoma; Netherlands; Norpregnadienes; Operative Time; Sutures; Uterine Myomectomy; Uterine Neoplasms | 2020 |
Effect on surgical decisions: Ulipristal acetate as key player in Belgian phase IV registration trial.
Topics: Adult; Belgium; Female; Humans; Leiomyoma; Norpregnadienes; Preoperative Period; Prospective Studies; Treatment Outcome; Uterine Myomectomy; Uterine Neoplasms | 2019 |
Preoperative Treatment with Ulipristal Acetate before Outpatient Hysteroscopic Myomectomy.
Topics: Adult; Ambulatory Surgical Procedures; Combined Modality Therapy; Contraceptive Agents, Hormonal; Female; Humans; Hysteroscopy; Leiomyoma; Middle Aged; Norpregnadienes; Operative Time; Patient Preference; Pregnancy; Preoperative Care; Prospective Studies; Treatment Outcome; Uterine Myomectomy; Uterine Neoplasms | 2020 |
Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids.
Topics: Adult; Female; Fertilization in Vitro; Humans; Infertility, Female; Leiomyoma; Norpregnadienes; Preconception Care; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Rate; Treatment Outcome; Uterine Neoplasms; Uterus | 2020 |
Ulipristal acetate versus gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): Long term results of a double-blind randomized controlled trial.
Topics: Female; Gonadotropin-Releasing Hormone; Humans; Laparoscopy; Netherlands; Norpregnadienes; Quality of Life; Uterine Myomectomy; Uterine Neoplasms | 2020 |
Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
Topics: Adult; Amenorrhea; Double-Blind Method; Female; Humans; Japan; Leiomyoma; Leuprolide; Menorrhagia; Middle Aged; Norpregnadienes; Time Factors; Treatment Outcome; Uterine Neoplasms | 2021 |
Ulipristal Acetate and Extracellular Matrix Production in Human Leiomyomas In Vivo: A Laboratory Analysis of a Randomized Placebo Controlled Trial.
Topics: Antineoplastic Agents, Hormonal; Double-Blind Method; Extracellular Matrix; Extracellular Matrix Proteins; Female; Humans; Leiomyoma; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myometrium; Norpregnadienes; Uterine Neoplasms | 2018 |
Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Hormone Antagonists; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Treatment Outcome; Uterine Neoplasms | 2018 |
Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Cross-Over Studies; Double-Blind Method; Female; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Quality of Life; Surveys and Questionnaires; Symptom Assessment; Uterine Hemorrhage; Uterine Neoplasms | 2018 |
Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Topics: Adolescent; Adult; Amenorrhea; Double-Blind Method; Female; Humans; Leiomyoma; Menorrhagia; Middle Aged; Norpregnadienes; Uterine Hemorrhage; Uterine Neoplasms | 2014 |
Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Topics: Administration, Oral; Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Drug Administration Schedule; Endometrium; Europe; Female; Humans; Leiomyoma; Menorrhagia; Middle Aged; Norethindrone; Norethindrone Acetate; Norpregnadienes; Pelvic Pain; Quality of Life; Time Factors; Treatment Outcome; Tumor Burden; Uterine Neoplasms | 2014 |
First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids.
Topics: Abortion, Spontaneous; Adult; Antineoplastic Agents; Contraceptive Agents; Female; Humans; Leiomyoma; Live Birth; Norpregnadienes; Pilot Projects; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Treatment Outcome; Uterine Neoplasms | 2014 |
Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.
Topics: Administration, Oral; Adult; Amenorrhea; Double-Blind Method; Female; Headache; Humans; Leiomyoma; Middle Aged; Nausea; Norpregnadienes; Pain; Quality of Life; Treatment Outcome; Uterine Neoplasms | 2015 |
In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment.
Topics: Adult; Contraceptive Agents; Double-Blind Method; Female; Humans; Leiomyoma; Middle Aged; Myoma; Norpregnadienes; Preoperative Care; Treatment Outcome; Uterine Neoplasms | 2015 |
Long-term medical management of uterine fibroids with ulipristal acetate.
Topics: Adolescent; Adult; Antineoplastic Agents; Biopsy; Double-Blind Method; Drug Administration Schedule; Europe; Female; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Pain Measurement; Pelvic Pain; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome; Uterine Hemorrhage; Uterine Neoplasms; Young Adult | 2016 |
Ulipristal acetate versus placebo for fibroid treatment before surgery.
Topics: Administration, Oral; Adult; Anemia; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Leiomyoma; Menorrhagia; Middle Aged; Norpregnadienes; Receptors, Progesterone; Uterine Neoplasms; Uterus; Young Adult | 2012 |
Ulipristal acetate versus leuprolide acetate for uterine fibroids.
Topics: Administration, Oral; Adult; Double-Blind Method; Endometrium; Female; Humans; Injections, Intramuscular; Intention to Treat Analysis; Leiomyoma; Leuprolide; Menorrhagia; Middle Aged; Norpregnadienes; Uterine Neoplasms; Young Adult | 2012 |
Other Studies
76 other study(ies) available for ulipristal acetate and Uterine Neoplasms
Article | Year |
---|---|
Molecular subclass of uterine fibroids predicts tumor shrinkage in response to ulipristal acetate.
Topics: Female; Humans; Leiomyoma; Receptors, Progesterone; Retrospective Studies; Transcription Factors; Uterine Neoplasms | 2023 |
Effects of long-term intermittent pharmacological therapy with ulipristal acetate on reducing the volume of uterine fibroids and relieving symptoms.
Topics: Adult; Contraceptive Agents, Female; Contraceptive Agents, Hormonal; Female; Humans; Leiomyoma; Menorrhagia; Middle Aged; Norpregnadienes; Treatment Outcome; Uterine Neoplasms | 2023 |
Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma.
Topics: Animals; Cell Death; Chemokine CCL2; DNA, Complementary; Female; Humans; Leiomyoma; Mice; Receptors, Progesterone; Sarcoma; Signal Transduction; STAT3 Transcription Factor; Uterine Neoplasms | 2023 |
Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study.
Topics: Adolescent; Adult; Female; Humans; Italy; Leiomyoma; Middle Aged; Norpregnadienes; Retrospective Studies; Treatment Outcome; Uterine Neoplasms; Young Adult | 2020 |
Guideline No. 389-Medical Management of Symptomatic Uterine Leiomyomas - An Addendum.
Topics: Anemia; Antineoplastic Agents, Hormonal; Contraceptive Agents, Hormonal; Female; Gonadotropin-Releasing Hormone; Hematinics; Humans; Iron Compounds; Leiomyoma; Leuprolide; Liver Function Tests; Menorrhagia; Norpregnadienes; Uterine Neoplasms | 2019 |
Laparoscopic myomectomy after or without pre-treatment with ulipristal acetate.
Topics: Female; Humans; Laparoscopy; Norpregnadienes; Pregnancy; Uterine Myomectomy; Uterine Neoplasms | 2021 |
Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience.
Topics: Adult; Contraceptive Agents, Hormonal; Cross-Sectional Studies; Female; Humans; Leiomyoma; Liver; Liver Function Tests; Middle Aged; Norpregnadienes; Uterine Neoplasms | 2020 |
The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor.
Topics: Adult; Animals; Cell Line, Tumor; Dexamethasone; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Leiomyoma; Mice; Models, Animal; Norpregnadienes; Period Circadian Proteins; Primary Cell Culture; Product Surveillance, Postmarketing; Receptors, Glucocorticoid; Signal Transduction; Tacrolimus Binding Proteins; Transcription Factors; Uterine Neoplasms; Uterus | 2020 |
Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: A pilot study.
Topics: Adult; Antineoplastic Agents, Hormonal; Female; Humans; Leiomyoma; Leuprolide; Neovascularization, Pathologic; Netherlands; Norpregnadienes; Pilot Projects; Premenopause; Treatment Outcome; Tumor Burden; Uterine Neoplasms | 2020 |
EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
Topics: Animals; Cell Proliferation; Contraceptive Agents, Female; Estrenes; Female; Humans; Leiomyoma; Mice; Molecular Docking Simulation; Molecular Structure; Norpregnadienes; Oximes; Progesterone Congeners; Receptors, Progesterone; Structure-Activity Relationship; Uterine Neoplasms; Uterus; Xenograft Model Antitumor Assays | 2019 |
Autophagy up-regulation by ulipristal acetate as a novel target mechanism in the treatment of uterine leiomyoma: an in vitro study.
Topics: Adult; Antineoplastic Agents, Hormonal; Autophagy; Autophagy-Related Proteins; Female; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Signal Transduction; Tumor Cells, Cultured; Uterine Neoplasms | 2019 |
Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases.
Topics: Blood Transfusion; Emergencies; Female; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Rupture, Spontaneous; Uterine Hemorrhage; Uterine Neoplasms | 2020 |
What does non-eligibility for myoma surgery mean in the context of sequential prescription of ulipristal acetate?
Topics: Chemical and Drug Induced Liver Injury; Contraindications, Procedure; Female; Humans; Leiomyoma; Norpregnadienes; Risk Factors; Uterine Myomectomy; Uterine Neoplasms | 2020 |
An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids.
Topics: Chemical and Drug Induced Liver Injury; Female; Humans; Leiomyoma; Norpregnadienes; Product Surveillance, Postmarketing; United States; Uterine Neoplasms | 2020 |
Suspension of ulipristal acetate for uterine fibroids during ongoing EMA's review of liver injury risk: Unfortunate timing during the Covid-19 pandemic!
Topics: Adult; Aged; Betacoronavirus; Chemical and Drug Induced Liver Injury; Coronavirus Infections; COVID-19; Female; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Pandemics; Pneumonia, Viral; Risk Assessment; Risk Factors; Safety-Based Drug Withdrawals; SARS-CoV-2; Substance Withdrawal Syndrome; Uterine Neoplasms; Withholding Treatment | 2020 |
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis.
Topics: Chemical and Drug Induced Liver Injury; Confounding Factors, Epidemiologic; Female; Humans; Leiomyoma; Norpregnadienes; Pharmacovigilance; Retrospective Studies; United States; Uterine Neoplasms | 2020 |
Hysteroscopic and ultrasonographic evaluation of ulipristal acetate treatment for symptomatic myomas in premenopausal women: a prospective study.
Topics: Female; Humans; Hysteroscopy; Leiomyoma; Myoma; Norpregnadienes; Pregnancy; Prospective Studies; Uterine Neoplasms | 2022 |
Treatment Choices in a National Cohort of Canadian Women With Symptomatic Uterine Fibroids.
Topics: Adult; Canada; Contraceptive Agents, Female; Contraceptive Agents, Hormonal; Female; Gonadotropin-Releasing Hormone; Humans; Hysterectomy; Leiomyoma; Middle Aged; Norpregnadienes; Pregnancy; Treatment Outcome; Uterine Myomectomy; Uterine Neoplasms; Watchful Waiting | 2020 |
Proteins involved in oxidative stress in leiomyoma tissues treated with ulipristal acetate.
Topics: Adult; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Hydrogen Peroxide; Leiomyoma; Mass Spectrometry; Norpregnadienes; Oxidative Stress; Protein Interaction Maps; Proteomics; Reactive Oxygen Species; Uterine Neoplasms | 2021 |
Use of Ulipristal Acetate and Risk of Liver Disease: A Nationwide Cohort Study.
Topics: Adult; Chemical and Drug Induced Liver Injury; Cohort Studies; Female; Humans; Incidence; Leiomyoma; Liver Diseases; Middle Aged; Norpregnadienes; Republic of Korea; Retrospective Studies; Risk Factors; Uterine Hemorrhage; Uterine Neoplasms | 2021 |
Nutraceuticals in fibroid management after ulipristal acetate administration: An observational study on patients' compliance.
Topics: Adult; Dietary Supplements; Female; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Quality of Life; Uterine Neoplasms | 2022 |
The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Topics: Adenomyosis; Adult; Cross-Sectional Studies; Endometrium; Female; Gene Expression Regulation; Humans; Leiomyoma; Ligands; Menorrhagia; Middle Aged; Norpregnadienes; Receptors, Progesterone; RNA, Messenger; Time Factors; Treatment Outcome; Uterine Neoplasms | 2021 |
Pharmacokinetics, toxicological and clinical aspects of ulipristal acetate: insights into the mechanisms implicated in the hepatic toxicity.
Topics: Chemical and Drug Induced Liver Injury; Female; Humans; Leiomyoma; Norpregnadienes; Uterine Neoplasms | 2021 |
Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up.
Topics: Adult; Contraceptive Agents, Hormonal; Female; Humans; Legislation, Drug; Leiomyoma; Middle Aged; Norpregnadienes; Prospective Studies; Quality of Life; Risk Factors; Uterine Neoplasms | 2021 |
Phase III long-term study to evaluate the efficacy and safety of ulipristal acetate in Japanese patients with uterine fibroids.
Topics: Female; Humans; Japan; Leiomyoma; Norpregnadienes; Quality of Life; Uterine Neoplasms | 2021 |
Inefficiency of ulipristal acetate on uterus leiomyomas as an additional sign to suspect leiomyosarcoma.
Topics: Adult; Combined Modality Therapy; Diagnosis, Differential; Drug Resistance, Neoplasm; Female; Humans; Hysterectomy; Leiomyoma; Leiomyosarcoma; Morcellation; Norpregnadienes; Preoperative Care; Treatment Failure; Tumor Burden; Uterine Neoplasms | 2017 |
Real-world data of 197 patients treated with ulipristal acetate for uterine fibroids: PREMYA study French population main outcomes.
Topics: Adult; Combined Modality Therapy; Female; France; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Practice Patterns, Physicians'; Preoperative Period; Prospective Studies; Quality of Life; Treatment Outcome; Uterine Neoplasms | 2017 |
Selective Progesterone Receptor Modulators for the Treatment of Uterine Leiomyomas.
Topics: Female; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Norpregnadienes; Receptors, Progesterone; Uterine Neoplasms | 2017 |
Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Cost Savings; Databases, Factual; Female; France; Gynecologic Surgical Procedures; Humans; Leiomyoma; Linear Models; Middle Aged; Norpregnadienes; Retrospective Studies; Uterine Neoplasms; Young Adult | 2017 |
Endometrial Changes in Surgical Specimens of Perimenopausal Patients Treated With Ulipristal Acetate for Uterine Leiomyomas.
Topics: Adult; Endometrium; Female; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Perimenopause; Uterine Neoplasms | 2018 |
Progesterone Receptor Isoforms, Nuclear Corepressor-1 and Steroid Receptor Coactivator-1 and B-Cell Lymphoma 2 and Akt and Akt Phosphorylation Status in Uterine Myomas after Ulipristal Acetate Treatment: A Systematic Immunohistochemical Evaluation.
Topics: Adult; Case-Control Studies; Co-Repressor Proteins; Female; Humans; Leiomyoma; Norpregnadienes; Nuclear Receptor Coactivator 1; Phosphorylation; Prospective Studies; Protein Isoforms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Receptors, Progesterone; Uterine Neoplasms | 2018 |
Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy.
Topics: Adult; Antineoplastic Agents, Hormonal; Cohort Studies; Contraceptives, Oral, Hormonal; Drug Resistance; Female; France; Hospitals, University; Humans; Leiomyoma; Leiomyomatosis; Magnetic Resonance Imaging; Menorrhagia; Norpregnadienes; Pelvic Pain; Retrospective Studies; Slovenia; Tumor Burden; Ultrasonography; Uterine Neoplasms; Young Adult | 2018 |
Ulipristal acetate for pre-operative management of uterine fibroids: Modeling outcomes and costs.
Topics: Adult; Cohort Studies; Combined Modality Therapy; Contraceptives, Oral, Hormonal; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Hysterectomy; Italy; Leiomyoma; Leiomyomatosis; Models, Economic; Norpregnadienes; Preoperative Care; Quality of Life; Randomized Controlled Trials as Topic; Tumor Burden; Uterine Artery Embolization; Uterine Hemorrhage; Uterine Myomectomy; Uterine Neoplasms | 2018 |
Matrix Metalloproteinase Activity Correlates With Uterine Myoma Volume Reduction After Ulipristal Acetate Treatment.
Topics: Female; Humans; Leiomyoma; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Norpregnadienes; Prospective Studies; Tissue Inhibitor of Metalloproteinase-1; Tumor Burden; Uterine Neoplasms | 2018 |
Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids.
Topics: Adult; Age Factors; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Body Mass Index; Down-Regulation; Female; Hospitals, University; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Retrospective Studies; Time Factors; Transforming Growth Factor beta3; Treatment Outcome; Uterine Neoplasms; Young Adult | 2018 |
Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Topics: Adult; Contraceptive Agents, Female; England; Female; Humans; Leiomyoma; Menorrhagia; Middle Aged; Norpregnadienes; Treatment Outcome; Uterine Neoplasms; Young Adult | 2018 |
Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Topics: Adult; Contraceptive Agents, Female; Female; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Retrospective Studies; Treatment Outcome; Uterine Neoplasms | 2018 |
Gene expression changes in uterine myomas in response to ulipristal acetate treatment.
Topics: Female; Gene Expression; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Treatment Outcome; Uterine Neoplasms; Uterus | 2018 |
Failure of ulipristal acetate treatment as an indication for uterine malignancy: Two case reports.
Topics: Diagnosis, Differential; Female; Humans; Leiomyoma; Leiomyosarcoma; Middle Aged; Morcellation; Norpregnadienes; Uterine Myomectomy; Uterine Neoplasms | 2018 |
A-Kinase Anchoring Protein 13 (AKAP13) Augments Progesterone Signaling in Uterine Fibroid Cells.
Topics: A Kinase Anchor Proteins; Adult; Animals; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Female; Gene Knockdown Techniques; Humans; Leiomyoma; MAP Kinase Signaling System; Mechanotransduction, Cellular; Middle Aged; Minor Histocompatibility Antigens; Norpregnadienes; Progesterone; Proto-Oncogene Proteins; Receptors, Progesterone; RNA, Small Interfering; Uterine Neoplasms; Uterus | 2019 |
[Ulipristal acetate and SPRM: A new entity for the therapeutic strategy for symptomatic myomas].
Topics: Adult; Female; Humans; Leiomyoma; Norpregnadienes; Receptors, Progesterone; Uterine Neoplasms | 2018 |
Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids.
Topics: Adenomyosis; Diagnostic Errors; Disease Progression; Female; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Ultrasonography; Uterine Neoplasms; Uterus | 2019 |
Sonographic and hysteroscopic endometrial examination in women treated with ulipristal acetate: Exploratory findings at a tertiary referral center.
Topics: Adult; Endometrium; Female; Humans; Hysteroscopy; Leiomyomatosis; Middle Aged; Norpregnadienes; Prospective Studies; Ultrasonography; Uterine Neoplasms | 2019 |
Ulipristal Acetate Mediates Decreased Proteoglycan Expression Through Regulation of Nuclear Factor of Activated T-Cells (NFAT5).
Topics: Extracellular Matrix; Female; Humans; Leiomyoma; NFATC Transcription Factors; Norpregnadienes; Proteoglycans; Uterine Neoplasms | 2019 |
Potential synergism between ulipristal acetate and vitamin D3 in uterine fibroid pharmacotherapy - 2 case studies.
Topics: Adult; Antineoplastic Agents, Hormonal; Cholecalciferol; Drug Synergism; Drug Therapy, Combination; Female; Humans; Leiomyomatosis; Middle Aged; Norpregnadienes; Treatment Outcome; Uterine Neoplasms | 2019 |
Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and/or adenomyosis.
Topics: Adenomyosis; Adult; Contraceptive Agents, Female; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Receptors, Progesterone; Uterine Neoplasms; Young Adult | 2019 |
Pathologic Changes in Uterine Leiomyomas After Extended Treatment With Ulipristal Acetate.
Topics: Adult; Contraceptive Agents, Hormonal; Female; Humans; Leiomyoma; Myometrium; Norpregnadienes; Uterine Neoplasms | 2020 |
Repeated two cycles of ulipristal acetate treatment improve the quality of life in premenopausal women with heavy menstrual bleeding dependent on uterine myomas, without impairment of bone health.
Topics: Adult; Bone Density; Drug Administration Schedule; Female; Humans; Italy; Leiomyoma; Menorrhagia; Middle Aged; Norpregnadienes; Quality of Life; Treatment Outcome; Uterine Neoplasms | 2019 |
Which is the destiny of ulipristal acetate for uterine fibroids? A commentary on the Italian medicines agency (AIFA) pronouncements
Topics: Chemical and Drug Induced Liver Injury; Contraceptive Agents, Female; Female; Humans; Italy; Leiomyoma; Liver Function Tests; Norpregnadienes; Time Factors; Uterine Neoplasms | 2019 |
Ulipristal acetate decreases active TGF-β3 and its canonical signaling in uterine leiomyoma via two novel mechanisms.
Topics: Adult; Cells, Cultured; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Leiomyoma; Norpregnadienes; Primary Cell Culture; Signal Transduction; Transforming Growth Factor beta3; Uterine Neoplasms | 2019 |
Absence of predictable long-term molecular effect of ulipristal acetate (UPA) on the endometrium.
Topics: Adult; Cell Proliferation; Contraceptive Agents, Hormonal; Endometrium; Female; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Receptors, Estrogen; Receptors, Progesterone; Uterine Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Disappearance of a myoma after pregnancy in a 38 years old patient, treated by ulipristal acetate without success before getting pregnant.
Topics: Adult; Contraceptive Agents, Hormonal; Female; Humans; Leiomyoma; Magnetic Resonance Imaging; Norpregnadienes; Pregnancy; Remission, Spontaneous; Uterine Neoplasms | 2019 |
Ulipristal acetate on quality of life and sexual function of women with uterine fibromatosis.
Topics: Activities of Daily Living; Adult; Anxiety; Contraceptive Agents, Hormonal; Depression; Dysmenorrhea; Dyspareunia; Female; Humans; Leiomyoma; Libido; Menorrhagia; Metrorrhagia; Middle Aged; Neoplasms, Multiple Primary; Norpregnadienes; Pelvic Pain; Prospective Studies; Quality of Life; Sexual Dysfunction, Physiological; Sexual Health; Treatment Outcome; Uterine Neoplasms | 2020 |
The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids.
Topics: Adult; Cost-Benefit Analysis; Female; Humans; Leiomyoma; Models, Economic; Norpregnadienes; Uterine Neoplasms | 2014 |
[Ulipristal acetate (Esmya): a selective modulator of progesterone receptors, new treatment of uterine fibromatosis].
Topics: Female; Humans; Leiomyoma; Norpregnadienes; Progesterone; Receptors, Progesterone; Uterine Neoplasms | 2014 |
Application of ulipristal acetate in female patients with uterine fibroids.
Topics: Administration, Oral; Adult; Female; Hormone Antagonists; Humans; Leiomyoma; Menstruation Disturbances; Middle Aged; Norpregnadienes; Receptors, Progesterone; Treatment Outcome; Tumor Burden; Uterine Neoplasms | 2014 |
Ulipristal acetate modulates the expression and functions of activin a in leiomyoma cells.
Topics: Activins; Adult; Female; Gene Expression Regulation, Neoplastic; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Tumor Cells, Cultured; Uterine Neoplasms | 2014 |
Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Topics: Female; Humans; Leiomyoma; Norpregnadienes; Receptors, Progesterone; Severity of Illness Index; Uterine Neoplasms | 2014 |
Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
Topics: Adult; Antineoplastic Agents, Hormonal; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers; Caspase 3; Cell Proliferation; Combined Modality Therapy; Female; Gene Expression Regulation, Neoplastic; Humans; Leiomyoma; Leuprolide; Middle Aged; Myometrium; Neoplasm Proteins; Norpregnadienes; Proliferating Cell Nuclear Antigen; Receptor, Platelet-Derived Growth Factor alpha; Receptors, LHRH; Receptors, Progesterone; Uterine Neoplasms | 2015 |
Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study.
Topics: Adult; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Attitude of Health Personnel; Contraceptive Agents; Female; Humans; Hysteroscopy; Leiomyoma; Letrozole; Nitriles; Norpregnadienes; Operative Time; Pain, Postoperative; Patient Satisfaction; Pilot Projects; Prospective Studies; Triazoles; Triptorelin Pamoate; Tumor Burden; Uterine Neoplasms | 2015 |
Pseudo-Meig's Syndrome in a Woman on Ulipristal Acetate.
Topics: Adult; Female; Humans; Leiomyoma; Meigs Syndrome; Norpregnadienes; Uterine Neoplasms | 2015 |
Spontaneous Pregnancy Following Ulipristal Acetate Treatment in a Woman with a Symptomatic Uterine Fibroid.
Topics: Abortion, Habitual; Adult; Contraceptive Agents; Delivery, Obstetric; Female; Fertilization; Humans; Leiomyoma; Norpregnadienes; Pregnancy; Pregnancy Outcome; Uterine Neoplasms | 2016 |
Use of Ulipristal Acetate for the Management of Fibroid-Related Acute Abnormal Uterine Bleeding.
Topics: Adult; Blood Transfusion; Contraceptive Agents; Female; Humans; Laparoscopy; Leiomyoma; Norpregnadienes; Severity of Illness Index; Treatment Outcome; Uterine Hemorrhage; Uterine Myomectomy; Uterine Neoplasms | 2016 |
Ulipristal acetate prior to in vitro fertilization in a female patient affected by uterine fibroids: a case report.
Topics: Adult; Biopsy; Endometrium; Female; Fertilization in Vitro; Fibroma; Humans; Infertility, Female; Leiomyoma; Norpregnadienes; Uterine Hemorrhage; Uterine Neoplasms | 2016 |
Repeated-intermittent use of ulipristal acetate for the management of uterine fibroids: an Italian pharmacoeconomic evaluation.
Topics: Cost-Benefit Analysis; Drug Administration Schedule; Economics, Pharmaceutical; Female; Humans; Italy; Leiomyoma; Norpregnadienes; Quality of Life; Randomized Controlled Trials as Topic; Uterine Neoplasms | 2016 |
Myoma migration: an unexpected "effect" with Ulipristal acetate treatment.
Topics: Female; Humans; Leiomyoma; Myoma; Neoplastic Cells, Circulating; Norpregnadienes; Pregnancy; Uterine Myomectomy; Uterine Neoplasms | 2016 |
[Diagnosis and treatment of uterine myoma].
Topics: Abortion, Habitual; Defecation; Female; Gonadotropin-Releasing Hormone; Humans; Hysteroscopy; Infertility, Female; Laparoscopy; Laparotomy; Leiomyoma; Norpregnadienes; Pelvic Pain; Precision Medicine; Urination Disorders; Uterine Hemorrhage; Uterine Neoplasms | 2016 |
Treatment with ulipristal acetate (Esmya(®)) and plasma levels of tacrolimus: a case report.
Topics: Adult; Cholangitis; Drug Interactions; Female; Humans; Hysterectomy; Immunosuppressive Agents; Leiomyomatosis; Liver Transplantation; Mycophenolic Acid; Norpregnadienes; Tacrolimus; Treatment Outcome; Uterine Neoplasms | 2016 |
Role of ethnicity in treating uterine fibroids with ulipristal acetate.
Topics: Adolescent; Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Black People; Female; Healthcare Disparities; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Ontario; Patient Satisfaction; Prospective Studies; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome; Uterine Neoplasms; White People; Young Adult | 2016 |
Unexpected Uterine Leiomyosarcoma During Laparoscopic Hysterectomy Treated 6 Months With Ulipristal Acetate and Contained Power Morcellation.
Topics: Delayed Diagnosis; Denmark; Disease Progression; Female; Humans; Hysterectomy; Intraoperative Period; Laparoscopy; Leiomyoma; Leiomyosarcoma; Lung Neoplasms; Menorrhagia; Middle Aged; Minimally Invasive Surgical Procedures; Morcellation; Norpregnadienes; Uterine Neoplasms | 2017 |
Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study.
Topics: Adult; Blood Loss, Surgical; Databases, Factual; Female; Humans; Laparoscopy; Leiomyomatosis; Norpregnadienes; Operative Time; Retrospective Studies; Treatment Outcome; Uterine Myomectomy; Uterine Neoplasms | 2016 |
Medical or surgical management of fibroids? An internet survey of gynecologists' views.
Topics: Attitude of Health Personnel; Clinical Decision-Making; Female; Fertility Preservation; Health Care Surveys; Humans; Hysterectomy; Internet; Leiomyoma; Norpregnadienes; Pregnancy; Progestins; Uterine Myomectomy; Uterine Neoplasms | 2017 |
Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results.
Topics: Abdominal Pain; Adult; Cohort Studies; Contraceptive Agents; European Union; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Hysterectomy; Leiomyoma; Leiomyomatosis; Middle Aged; Norpregnadienes; Organ Sparing Treatments; Prospective Studies; Quality of Life; Severity of Illness Index; Uterine Diseases; Uterine Hemorrhage; Uterine Myomectomy; Uterine Neoplasms | 2017 |
Histomorphological changes in endometriosis in a patient treated with ulipristal: A case report.
Topics: Adult; Endometriosis; Endometrium; Female; Humans; Leiomyoma; Norpregnadienes; Uterine Neoplasms | 2017 |
Uterine fibroids and evidence-based medicine--not an oxymoron.
Topics: Female; Humans; Leiomyoma; Leuprolide; Menorrhagia; Norpregnadienes; Receptors, Progesterone; Uterine Neoplasms | 2012 |
Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment.
Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Female; Hormone Antagonists; Humans; Leiomyoma; Menorrhagia; Mifepristone; Norpregnadienes; Progesterone; Receptors, Progesterone; Uterine Neoplasms | 2012 |